American Century Companies Inc. Increases Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

American Century Companies Inc. increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 0.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,604,024 shares of the biopharmaceutical company's stock after purchasing an additional 11,291 shares during the quarter. American Century Companies Inc. owned approximately 1.24% of Alnylam Pharmaceuticals worth $377,443,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ALNY. Allworth Financial LP boosted its stake in Alnylam Pharmaceuticals by 6.8% in the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company's stock worth $140,000 after buying an additional 38 shares in the last quarter. Nixon Peabody Trust Co. lifted its holdings in shares of Alnylam Pharmaceuticals by 1.9% in the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company's stock worth $540,000 after acquiring an additional 43 shares during the last quarter. IFP Advisors Inc boosted its stake in shares of Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 47 shares in the last quarter. Nwam LLC grew its holdings in shares of Alnylam Pharmaceuticals by 5.8% during the 4th quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company's stock valued at $213,000 after purchasing an additional 50 shares during the last quarter. Finally, SYM FINANCIAL Corp raised its position in Alnylam Pharmaceuticals by 6.2% in the 3rd quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company's stock worth $260,000 after purchasing an additional 55 shares during the period. 92.97% of the stock is owned by institutional investors.

Remove Ads

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY traded down $11.75 during midday trading on Wednesday, hitting $269.21. 1,073,887 shares of the stock traded hands, compared to its average volume of 808,981. The firm has a market capitalization of $34.85 billion, a P/E ratio of -124.06 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The firm has a 50-day moving average of $258.98 and a two-hundred day moving average of $260.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on ALNY. Citigroup boosted their price objective on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research report on Friday, March 21st. HC Wainwright raised their price target on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a "buy" rating in a report on Monday, February 24th. William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Chardan Capital reiterated a "buy" rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Finally, JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $280.00 to $328.00 in a report on Monday. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty have assigned a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $312.30.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the sale, the chief executive officer now directly owns 81,526 shares of the company's stock, valued at approximately $20,802,989.42. This represents a 1.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the sale, the executive vice president now owns 14,321 shares in the company, valued at approximately $3,654,862.41. The trade was a 4.42 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is owned by insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.